Cancer Letters
Volume 220, Issue 1 , Pages 57-65 , 18 March 2005

Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen

  • Joon Song

      Affiliations

    • Department of Obstetrics and Gynecology, Yale University, P.O. Box 208063, 333 Cedar Street, FMB 331, New Haven, CT 06520-8063, USA
    • ,
  • Ahmed Fadiel

      Affiliations

    • Department of Obstetrics and Gynecology, Yale University, P.O. Box 208063, 333 Cedar Street, FMB 331, New Haven, CT 06520-8063, USA
    • ,
  • Valentine Edusa

      Affiliations

    • Department of Obstetrics and Gynecology, Yale University, P.O. Box 208063, 333 Cedar Street, FMB 331, New Haven, CT 06520-8063, USA
    • ,
  • Zhaocong Chen

      Affiliations

    • Department of Obstetrics and Gynecology, Yale University, P.O. Box 208063, 333 Cedar Street, FMB 331, New Haven, CT 06520-8063, USA
    • ,
  • John So

      Affiliations

    • Department of Obstetrics and Gynecology, NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA
    • Tel.: +1-212-263-7141.
    • ,
  • Hideki Sakamoto

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Nihon University, 30-1 Oyaguchi-Kamimachi, Itabashi-ku, Tokyo 173, Japan
    • Tel.: +81-3-3972-8111.
    • ,
  • David A. Fishman

      Affiliations

    • Department of Obstetrics and Gynecology, NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA
    • Tel.: +1-212-263-7141.
    • ,
  • Frederick Naftolin

      Affiliations

    • Department of Obstetrics and Gynecology, Yale University, P.O. Box 208063, 333 Cedar Street, FMB 331, New Haven, CT 06520-8063, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-203-785-4003; fax: +1-203-785-5294.

Received 25 September 2003 ,Revised 14 January 2004 ,Accepted 3 April 2004.

References 

  1. Wingo PA, Ries LA, Parker SL, Heath CW. Cancer Epidemiol. Biomarkers Prev. 1998;7:271–282
  2. Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW. CA Cancer J. Clin. 1998;48:31–48
  3. Cianti C. Clin. Ter. 2002;153:135–144
  4. Wang J, Li AJ, Karlan BY. Curr. Womens Health Rep. 2002;2:20–26
  5. Auersperg N, Ota T, Mitchell GW. Int. J. Gynecol. Cancer. 2002;12:691–703
  6. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Lancet. 2002;359(9306):572–577
  7. Parker SL, Tong T, Bolden S, Wingo PA. CA Cancer J. Clin. 1996;46:5–27
  8. Schwartz P, Naftolin F. In: Practical Gynecologic Oncology. second ed.. 1994;p. 613–635
  9. Clinton GM, Hua W. Crit. Rev. Oncol. Hematol. 1997;25:1–9
  10. Lau KM, Mok SC, Ho SM. Proc. Nat. Acad. Sci. USA. 1999;96:5722–5727
  11. Chu S, Mamers P, Burger HG, Fuller PJ. J. Clin. Endocrinol. Metab. 2000;85:1200–1205
  12. Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, et al. Oncogene. 2002;21:1097–1107
  13. Challis JR. J. Endocrinol. 1974;107–115
  14. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. J. Steroid Biochem. Mol. Biol. 1995;55:279–289
  15. Jordan VC. Lancet Oncol. 2000;1:43–49
  16. Senior K. Lancet Oncol. 2001;2:466
  17. Keith Bechtel M, Bonavida B. Gynecol. Oncol. 2001;82:127–138
  18. Gould K, Bretscher A, Esch F, Hunter T. Eur. Med. Biol. Org. J. 1989;8(13):4133–4142
  19. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F. Cancer Lett. 1999;147(1–2):31–38
  20. Chen Z, Fadiel A, Feng Y, Ohtani K, Rutherford T, Naftolin F. Cancer. 2001;92(12):3068–3075
  21. Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. Neurobiol. Dis. 2001;8:266–278
  22. Scherer SS, Xu T, Crino P, Arroyo EJ, Gutmann DH. J. Neurosci. Res. 2001;65:150–164
  23. Smith WJ, Nassar N, Bretscher A, Cerione RA, Karplus PA. J. Biol. Chem. 2003;278:4949–4956
  24. Polesello C, Delon I, Valenti P, Ferrer P, Payre F. Nat. Cell Biol. 2002;4:782–789
  25. Bretscher A, Edwards K, Fehon RG. Nat. Rev. Mol. Cell Biol. 2002;3:586–599
  26. Gautreau A, Louvard D, Arpin M. Curr. Opin. Cell Biol. 2002;14:104–109
  27. Pujol P, Rey J, Nirde P, Roger P, Gastaldi M, Laffargue F, et al. Cancer Res. 1998;58(23):5367–5373
  28. Garcia M, Derocq D, Platet N, Bonnet S, Brouillet JP, Touitou I, et al. J. Steroid Biochem. Mol. Biol. 1997;61:11–17
  29. Song J, Sapi E, Brown W, Nilsen J, Tartaro K, Kacinski B, et al. J. Clin. Invest. 2000;106(10):1209–1220
  30. Song J, Rutherford T, Naftolin F, Brown S, Mor G. Mol. Hum. Reprod. 2002;8(5):447–455
  31. Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth M. Biochem. Biophys. Res. Commun. 1999;258(2):395–400
  32. Makitie T, Carpen O, Vaheri A, Kivela T. Invest. Ophthalmol. Vis. Sci. 2001;42:2442–2449
  33. Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, et al. J. Steroid Biochem. Mol. Biol. 1998;65(1–6):163–168
  34. Prall OW, Rogan EM, Sutherland RL. J. Steroid Biochem. Mol. Biol. 1998;65:169–174
  35. Korach KS, McLachlan JA. Arch. Toxicol. Suppl. 1985;8:33–42
  36. Thenot S, Charpin M, Bonnet S, Cavailles V. Mol. Cell Endocrinol. 1999;156:85–93
  37. Chan S. Semin. Oncol. 2002;29:129–133
  38. Stack MS, Ellerbroek SM, Fishman DA. Int. J. Oncol. 1998;12:569–576
  39. Nilsen J, Mor G, Naftolin F. J. Neurobiol. 2000;43:64–78
  40. Hayashi S, Yoshida T. Nippon Rinsho. 2000;58:495–503
  41. Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Breast Cancer Res. Treat. 2002;71:249–255
  42. Lacey JJ, Mink P, Lubin J, Sherman M, Troisi R, Hartge P, et al. J. Am. Med. Assoc. 2002;288(3):334–341
  43. MacLusky NJ, Voit R, Lazo JS, Schwartz PE, Merion MJ, Eisenfeld AH, et al. Steroids. 1987;50:423–433
  44. Santen RJ, Yue W, Naftolin F, Mor G, Berstein L. Endocr. Relat. Cancer. 1999;6:235–243

PII: S0304-3835(04)00374-X

doi: 10.1016/j.canlet.2004.04.024

Cancer Letters
Volume 220, Issue 1 , Pages 57-65 , 18 March 2005

Article Tools

* Image Usage & Resolution